Kidney Cancer Diagnostics Market
Kidney Cancer Diagnostics Market By Indication (Renal Cell Carcinoma, Transitional Cell Carcinoma, Kidney Sarcoma, Wilms Tumor & Kidney Lymphoma Kidney Cancer), By Test, By End User - Forecast to 2021–2031
Kidney Cancer Diagnostics Market outlook
The global kidney cancer diagnostics market reached a valuation of around US$ 600 Mn in 2020, and is slated to accelerate at a CAGR of 7% through 2031.
|Market Size Value in 2020||US$ 600 Mn|
|Market Forecast Value for 2031||US$ 1.2 Bn|
|Global Growth Rate||CAGR 7%|
|Share of Top 5 Companies||50%|
Demand for immunohistochemistry tests is set to increase at a CAGR of 6% across the assessment period of 2021 to 2031. Overall, the worldwide kidney cancer diagnostics market is set to top US$ 1.2 Bn by 2031.
Avail customized purchase options for your needs
Demand Analysis of Kidney Cancer Diagnostics from 2016 to 2020 Vs Market Outlook for 2021 to 2031
As per Fact.MR, a market research and competitive intelligence provider, the global market for kidney cancer diagnostics was valued at US$ 600 Mn in 2020.
The number of people living with kidney cancer has increased rapidly in recent years. Kidney cancer has been observed to occur primarily in the geriatric population, which is expected to drive growth of the global kidney cancer diagnostics market over the coming years and decades.
Several government agencies and private organizations from around the world are working to raise awareness about kidney cancer. Major factor driving growth of the market is increasing mindfulness and lifestyle change among people.
With increasing prevalence of kidney cancer, future generations will see a more accessible, affordable, and diagnosis-associated treatment for kidney cancer. Technological developments in devices, rise in healthcare spending, and growing demand for blood chemistry tests for kidney cancer diagnostics are driving market expansion, which expected to expand at 7% CAGR across the 2021 to 2031 assessment period.
How is Technological Innovation in Medical Devices Reshaping the Market for Kidney Cancer Diagnostics?
The medical device industry is a diverse, innovative, and dynamic sector. Technology is evolving rapidly and transforming the healthcare industry, from telemedicine to artificial intelligence, robotic surgery, and 3D printing.
Increased investments in the healthcare sector by public and government bodies and growing demand for kidney cancer molecular diagnostics are boosting the market. Prominent diagnostic tools will almost certainly be replaced by improved versions. With focus on R&D, governments around the world are taking various steps towards strengthening kidney cancer diagnostic systems.
Manufacturers of kidney cancer diagnostic systems and healthcare service providers have begun to provide personalized patient care for renal cell carcinoma kidney cancer treatment as well as access complete end-to-end medical device products and services. They are concentrating on developing and improving product prototyping as well as lowering operational costs.
The global market for kidney cancer diagnostics is also expected to see the emergence of new tests that can simultaneously decelerate the pace of tumor maturation between multiple stages of kidney cancer due to advancements in medical technology.
An Adaptive Approach to Modern-day Research Needs
What are the Restraints being Faced by Kidney Cancer Diagnostic Device Providers?
Numerous regulatory studies are required to gain approvals, and, as such, it is extremely costly to move findings from the development stage to the market for commercial use.
Majority of kidney cancer cases are diagnosed at an advanced stage. The severity of cancer and its diagnosis play a significant role in patients' and physicians' decisions to pay the high cost of treatment even if the outcome is only marginally improved. Low success rate in clinical trials and high cost may hinder growth of the overall cancer diagnostics market over the forecast period.
Which Region is a Lucrative Market for Kidney Cancer Diagnostic Device Manufacturers?
North America is a global market leader in kidney cancer diagnostics and is anticipated to stay the most dominant region; revenue in the North America region is expected to double by 2031.
Increased R&D spending by pharmaceutical companies and rising incidences of the ageing population are expected to drive urological medical device market growth in the region.
An increasing number of people are being diagnosed with kidney cancer in North America. Growing demand for complete blood count tests for kidney cancer diagnostics is likely to boost the market.
Rising opportunities for leading manufacturers of kidney diagnostic devices in Germany and growing demand for urine tests for kidney cancer diagnostics in Russia are contributing to the global market growth prospects.
What is the Kidney Cancer Diagnostics Demand Outlook for the U.S.?
The U.S. kidney cancer diagnostics market is expected to increase 1.4X by 2031. According to GLOBOCAN 2018 statistics, the estimated number of kidney cancer cases in the United States was 60,336.
Due to increase in the number of patients with chronic diseases, prevalence of kidney cancer, and high number of healthcare facilities in the country, the market in the U.S. is expected to experience high revenue growth.
High healthcare spending, latest advancements in diagnostic devices for transitional cell carcinoma kidney cancer treatment, and presence of favorable reimbursement policies are expected to drive growth of the market in the U.S.
Why is Demand for Kidney Cancer Diagnostics High in China?
In China, sales of kidney cancer diagnostics devices are increasing rapidly. Growing patient consciousness, lower drug production costs, and increasing patient base suffering from diseases such as renal cell carcinoma are expected to propel the market in China.
Companies are focusing on expanding their product portfolios, diversifying their business operations, lowering costs, improving user satisfaction, and improving kidney cancer diagnostic reliability in China, where business prospects are bright.
Interested to Procure The Data
Why are Immunohistochemistry Tests Gaining Immense Popularity?
Other segments are expected to grow slowly, while demand for immunohistochemistry tests for kidney cancer diagnostics is expected to increase 2.2X over the forecast period.
Rise in cancer incidence is a major factor driving market growth, as immunohistochemistry is commonly used to diagnose kidney cancer and other diseases involving antigen-antibody reactions. Immunohistochemistry is a microscopy technique used for identifying antigens and macromolecules found in cells and to find enzymes, tumor suppressor genes, antigens, and proliferation of tumor cells.
Immunohistochemical techniques have been applied more frequently in the diagnostic pathology of renal neoplasms. Demand for immunohistochemistry is growing due to increased product approvals and the emergence of immunohistochemistry solutions for kidney cancer diagnostics.
Over the coming years, demand for immunohistochemistry is expected to rise due to increased drug discovery and development activities, rising prevalence of chronic diseases, and increase in the number of diagnostic centers.
Will Hospital-associated Labs Remain Preferred for Kidney Cancer Diagnostics?
As hospitals and medical research organizations work to develop new diagnostic and therapeutic procedures, the burden of reducing the incidence of kidney cancer is passed onto them.
A urine sample is subjected to special tests in hospital-associated labs to look for small amounts of blood and other substances that aren't visible to the naked eye. Growing adoption of devices for the diagnosis of kidney cancer and major infections in hospital-associated labs is expected to drive market growth over the next ten years.
Many hospitals are increasing their capacity and using medical instruments for the diagnosis of kidney cancer, and they've implemented a variety of strategies to secure the necessary equipment, ensure sufficient workforce, and improve their facilities.
Impact of COVID-19 Crisis
COVID-19's rapid spread has resulted in significant changes in healthcare systems around the world. The procedures for diagnosing kidney cancer were postponed. Because of immune system problems, patients with renal cell carcinoma are more prone to infections.
COVID-19 is an unprecedented global public health crisis that has impacted sales of urological medical devices and is expected to have long-term consequences for the kidney cancer drugs market.
In the field of kidney cancer diagnostics, continued innovation is driving growth. Leading manufacturers of kidney diagnostic devices work with a sense of urgency and consumer focus in the post-pandemic era. Due to advancements in healthcare technologies and products, the kidney cancer molecular diagnostics market is expected to grow.
There are a large number of companies that are making significant contribution to kidney cancer treatment market growth.
Manufacturers of kidney cancer diagnosis instruments are partnering with regional health ministries and medical administrators to assess the therapeutic diagnosis's impact on kidney cancer patients. Medical organizations as well as leaders in the global pharmaceuticals industry are doubling down on the development of advanced kidney cancer diagnoses.
Market growth has been aided by product innovation and ongoing R&D activities to develop advanced technologies.
Kidney Cancer Diagnostics Industry Report Scope
|Historical Data Available for||2016-2020|
|Market Analysis||Value in US$ Mn, Volume in Cu. M|
|Key Regions Covered||
|Key Countries Covered||
|Key Market Segments Covered||
|Key Companies Profiled||
|Pricing||Available upon Request|
Key Segments Covered in Kidney Cancer Diagnostics Industry Research
- Immunohistochemistry Test for Kidney Cancer Diagnostics
- Complete Blood Count Test for Kidney Cancer Diagnostics
- Urine Test for Kidney Cancer Diagnostics
- Blood Chemistry Test for Kidney Cancer Diagnostics
- Renal Cell Carcinoma Kidney Cancer
- Transitional Cell Carcinoma Kidney Cancer
- Kidney Sarcoma Kidney Cancer
- Wilms Tumor Kidney Cancer
- Kidney Lymphoma Kidney Cancer
- Hospital-associated Labs for Kidney Cancer Diagnostics
- Independent Diagnostic Laboratories for Kidney Cancer Diagnostics
- Cancer Research Institutes for Kidney Cancer Diagnostics
- Metastatic Kidney Cancer Therapy
- Nephrectomy Therapy for Kidney Cancer
- Cytokine-based Treatment for Kidney Cancer
- Diagnostic Laboratories for Kidney Cancer
- Diagnostics Test for Kidney Cancer
- FAQs -
The global kidney cancer diagnostics market is currently worth more than US$ 600 Mn.
From 2016-2020, sales of kidney cancer diagnostic devices registered a CAGR of 4%.
Rise in the number of people living with kidney cancer and improvements in healthcare spending are factors are driving demand for kidney cancer diagnostics.
Myriad Genetics Inc., NeoGenomics Laboratories, NanoString Technologies Inc., Sysmex Corporation, and Rosetta Genomics are renowned kidney cancer diagnostic device manufacturers.
North America, with 50% global market share, will largely contribute to the growth of kidney cancer diagnostics revenue.
Sales of kidney cancer diagnostic devices in the U.K will most likely flourish at a CAGR of 4% over the next ten years.
Immunochemistry tests continue to be the highest revenue-generating segment, accounting for 40% of global revenue.
Sales of kidney cancer diagnostic devices in Canada are forecasted to reach over US$ 400 Mn by 2031.
The U.S., China, Germany, Japan, and Russia are expected to drive most demand for kidney cancer diagnostics.
The market is expected to top a value of US$ 1.2 Bn by the end of 2031, with sales revenue expected to register a CAGR of around 7%.
Need an Exclusive Report for your Unique Requirement?
- Related Reports -
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.